Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.47 |
| ▸ | ITGAV | P06756 | 6/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146616 | 1.00 | ROCK2 (0.48) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| Trifluoroacetic Acid SCHEMBL7146544 | 0.95 | ROCK1 (0.44) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7141416 | 0.94 | ROCK2 (0.45) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7137156 | 0.93 | ROCK2 (0.49) | ROCK2ROCK1ITGB3ITGAVKDR | |
| SCHEMBL7137153 | 0.93 | ROCK2 (0.49) | ROCK2ROCK1ITGB3ITGAVKDR | |
| SCHEMBL7147854 | 0.93 | ROCK2 (0.48) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7146289 | 0.93 | ROCK2 (0.52) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7146272 | 0.93 | ROCK2 (0.52) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7145301 | 0.90 | ITGB3 (0.44) | ROCK2ROCK1ITGB3ITGAVITGB1 | |
| SCHEMBL7143967 | 0.90 | ROCK2 (0.43) | ROCK2ROCK1ITGB3ITGAVITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | ROCK2 180/4885ROCK1 62/4885ITGB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.